Robert F. Kennedy Jr. continues to serve as HHS Secretary with active White House backing, as evidenced by his October 2026 congressional testimony, public appearances alongside administration officials, and leadership of MAHA policy initiatives on vaccines, nutrition, and agency reorganization. President Trump has publicly endorsed Kennedy’s agenda and directed messaging flexibility ahead of the midterms, with no official statements or credible reports indicating plans for removal. Earlier 2026 speculation about post-midterm changes has not materialized into action, and Kennedy’s recent comments emphasize the permanence of departmental shifts. Traders’ strong consensus against an exit by year-end reflects this sustained institutional support and the absence of triggering events such as resignation announcements or Senate pressure within the remaining resolution window.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · UpdatedView resolved

Beware of external links.
Beware of external links.
Frequently Asked Questions